Trial watch: Immune checkpoint blockers for cancer therapy
Open accessThe DOI matches its Crossref record; 317 of the 317 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications. Although considerable attention persists around the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1) signaling, several other co-inhibitory T-cell receptors are being evaluated as potential targets for the development of novel ICBs. Moreover, substantial efforts are being devoted to the identification of biomarkers that reliably predict the likelihood of each patient to obtain clinical benefits from ICBs in the absence of severe toxicity. Tailoring the delivery of specific ICBs or combinations thereof to selected patient populations in the context of precision medicine programs constitutes indeed a major objective of the future of ICB-based immunotherapy. Here, we discuss recent preclinical and clinical advances on the development of ICBs for oncological indications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibitors of lymphocyte activating 3 (LAG3), V-set immunoregulatory receptor (VSIR, best known as VISTA), and hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3), as well as drugs that block the NK-cell co-inhibitory receptor killer cell lectin-like receptor C1 (KLRC1, best known as NKG2A)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Vanpouille-Box et al., 2017
In the citing paper
“various ICIs targeting other co-inhibitory receptors are being extensively tested for efficacy in clinical trials”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Vanpouille-Box et al., 2017
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 9×
“(2) mediate clinical activity (at least to some extent) in a majority of scenarios.”
BackgroundInfluentialPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 1×
“the tumor microenvironment and the cancer mutational load.(64,67-74) However, the implementation of precision medi-”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×
“with squamous and non-squamous NSCLC whose disease progressed during or after platinum-based chemotherapy.(198,200)”
BackgroundNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“with squamous and non-squamous NSCLC whose disease progressed during or after platinum-based chemotherapy.(198,200)”
BackgroundCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“the treatment of adult and pediatric patients with unresectable or metastatic, MSI-H or dMMR malignancies.(35-37,280) The find-”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 1×
“the tumor microenvironment and the cancer mutational load.(64,67-74) However, the implementation of precision medi-”
BackgroundPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Research works printed but not linked: 3
- 2017, Cancer Discov., 7, 656
- Bezu L, 2015, Front Immunol., 6, 187
- Hammers HJ, 2017, J Clin Oncol., JCO2016721985
Cited by
Shae, D., Becker, K. W., Christov, P., Yun, D. S., Lytton-Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 668
Kociol, R. D., Cooper, L. T., Fang, J. C., Moslehi, J. J., Pang, P. S., Sabe, M. A., Shah, R. V., Sims, D. B., Thiene, G., Vardeny, O., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000745 · Cited by 625
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Locy, H., de Mey, S., de Mey, W., De Ridder, M., Thielemans, K., & Maenhout, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02909 · Cited by 279
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Smith, M., García-Martínez, E., Pitter, M. R., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526250 · Cited by 232
Metadata
- Authors
- Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., Zitvogel, L., Kroemer, G., & Galluzzi, L.
- Affiliations
- Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
- Weill Cornell Medicine (US)
- Inserm (FR)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Charles University (CZ)
- Sotio a.c., Prague, Czech Republic
- Université Paris-Sud (FR)
- Karolinska University Hospital (SE)
- Corresponding author
- Galluzzi, Lorenzo
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-08-31
- Volume
- 6
- Issue
- 11
- Pages
- e1373237
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5674958
- OpenAlex
- W2750667003
- Cited by
- 73
- References
- 316
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 7 · 2020: 7 · 2019: 18 · 2018: 22 · 2017: 1
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, CTLA-4, PD-1, biomarkers, predictive biomarkers, immunotherapy, precision medicine, cancer immunotherapy, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial watch: Immune checkpoint blockers for cancer therapy. https://app.cochat.ai/papers/10.1080/2162402x.2017.1373237
- The paper
- Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017). Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1373237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.